Canaccord Trims PT on Amarin (AMRN); Sees Increased Commercial Risk, Still Positive on NCE
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amarin (AMRN) in Focus as Traders Await NCE Decision on Vascepa
December 14, 2012 1:07 PM ESTAmarin (Nasdaq: AMRN) shares are higher on the session as traders anticipate an NCE decision on Vascepa sometime today, though nothing is in stone.
Shares are 24 percent lower from the close on December 6th, with Amarin... More
MKM Cuts PT on Amarin (AMRN) to $12; Sees 5% Chance of Partnering on Vascepa Now
December 7, 2012 10:54 AM ESTMKM Partners is keeping its Buy call on Amarin (Nasdaq: AMRN), but cutting its price target by $3 to $12 following Thursday's announcement of new financing and plans to hire more sales staff.
The firm notes that Amarin's moves indicate a "go-it-alone" strategy... More
Lazard Capital Cuts PT on Amarin (AMRN) to $16
December 7, 2012 10:39 AM ESTLazard Capital lowers its price target on Amarin Corporation (NASDAQ: AMRN) from $26 to $16 but maintains its Buy rating after go-it-alone news.
For an analyst ratings summary and ratings history on Amarin Corporation click... More
Jefferies Maintains Bullish Stance on Amarin (AMRN) Despite Self Commercialization News
December 7, 2012 8:00 AM ESTJefferies reiterated their Buy and $28 price target on Amarin Corporation (NASDAQ: AMRN) following the company's move to self-commercialize Vascepa.
The firm comments, "AMRN announced a decision to hire a salesforce to launch Vascepa in 1Q13 with a $100m non-dilutive debt... More
Amarin (AMRN) Still Risky into NCE Amid Vascepa Sales Staff Additions, Financing - Analyst
December 7, 2012 7:20 AM ESTAmarin (Nasdaq: AMRN) is in the dumps Friday morning following a news release Thursday night that it was entering a non-equity financing agreement for $100 million and hiring about 250 to 300 reps for its Vascepa launch.
Today, Wedbush is out with some comments on the news today.
Wedbush said the timing of the release was a surprise following... More
Amarin (AMRN) Enters $100M Non-Equity Financing Agreement; Hiring for Vascepa Sales Launch
December 6, 2012 4:03 PM ESTAmarin Corporation plc (Nasdaq: AMRN) announced today a $100 million non-equity financing with an investment fund managed by Pharmakon Advisors and that Amarin is continuing its preparations to commercialize Vascepa® (icosapent ethyl) capsules with the hiring of a sales force in the United States. Payments by Amarin under this hybrid debt-like instrument are expected to be made over a 3.5-year period commencing in November 2013 and to continue through early 2017.
As... More
